Higher expression levels of immune check points including PD-L1, CTLA-4, LAG-3 and TIM-3 was also validated in the SubA cohorts, suggesting those patients might be more sensitive to the immunotherapy of NSCLC (Figs. 1E, 2E). Here, HAVCR2 is linked to non-small cell lung carcinoma.